SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB BIO (Nasdaq: SABS) announced that Chairman and CEO Samuel J. Reich will participate in a fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference. The event will take place on November 11, 2024, at 3:00pm EST in Boston, MA. SAB BIO is a clinical-stage biopharmaceutical company developing a novel human anti-thymocyte immunoglobulin (hIgG) therapy aimed at delaying the onset or progression of type 1 diabetes. The fireside chat will be accessible via webcast, with a recording available through the company's website events section.
SAB BIO (Nasdaq: SABS) ha annunciato che il Presidente e CEO Samuel J. Reich parteciperà a una conversazione informale alla 2024 Guggenheim Securities Healthcare Innovation Conference. L'evento si terrà il 11 novembre 2024, alle 15:00 EST a Boston, MA. SAB BIO è un'azienda biofarmaceutica in fase clinica che sviluppa una nuova terapia con immunoglobulina anti-timo umana (hIgG) mirata a ritardare l'insorgenza o la progressione del diabete di tipo 1. La conversazione sarà accessibile tramite webcast, con una registrazione disponibile nella sezione eventi del sito web dell'azienda.
SAB BIO (Nasdaq: SABS) anunció que el Presidente y CEO Samuel J. Reich participará en una charla informal en la 2024 Guggenheim Securities Healthcare Innovation Conference. El evento tendrá lugar el 11 de noviembre de 2024, a las 3:00 p.m. EST en Boston, MA. SAB BIO es una empresa biofarmacéutica en etapa clínica que está desarrollando una nueva terapia con inmunoglobulina anti-timo humana (hIgG) destinada a retrasar la aparición o progresión de la diabetes tipo 1. La charla será accesible a través de un webcast, con una grabación disponible en la sección de eventos del sitio web de la empresa.
SAB BIO (Nasdaq: SABS)는 회장 겸 CEO인 Samuel J. Reich가 2024 Guggenheim Securities Healthcare Innovation Conference에서 대화에 참여할 것이라고 발표했습니다. 이 행사는 2024년 11월 11일 오후 3시 EST에 매사추세츠주 보스턴에서 열릴 예정입니다. SAB BIO는 제1형 당뇨병의 발병이나 진행을 지연시키기 위한 인간 항흉선 면역글로불린(hIgG) 치료제를 개발 중인 임상 단계의 생명공학 회사입니다. 대화는 웹캐스트를 통해 시청할 수 있으며, 회사 웹사이트의 이벤트 섹션에서 녹화본을 이용할 수 있습니다.
SAB BIO (Nasdaq: SABS) a annoncé que le Président et CEO Samuel J. Reich participera à une discussion informelle lors de la 2024 Guggenheim Securities Healthcare Innovation Conference. L'événement se déroulera le 11 novembre 2024 à 15h00 EST à Boston, MA. SAB BIO est une entreprise biopharmaceutique en phase clinique développant une nouvelle thérapie à base d'immunoglobuline anti-thymocyte humaine (hIgG) visant à retarder l'apparition ou la progression du diabète de type 1. La discussion sera accessible par webcast, avec un enregistrement disponible dans la section événements du site web de l'entreprise.
SAB BIO (Nasdaq: SABS) gab bekannt, dass der Vorsitzende und CEO Samuel J. Reich an einem Kaminabend bei der 2024 Guggenheim Securities Healthcare Innovation Conference teilnehmen wird. Die Veranstaltung findet am 11. November 2024 um 15:00 Uhr EST in Boston, MA, statt. SAB BIO ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das eine neuartige menschliche Anti-Thymozyten-Immunoglobulin (hIgG) Therapie entwickelt, die darauf abzielt, den Ausbruch oder das Fortschreiten von Typ-1-Diabetes zu verzögern. Der Kaminabend wird über einen Webcast zugänglich sein, wobei eine Aufzeichnung im Abschnitt Veranstaltungen der Unternehmenswebsite verfügbar sein wird.
- None.
- None.
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Chairman and CEO Samuel J. Reich will be speaking at an upcoming fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference held November 11th – 13th, 2024 in Boston, MA.
Event Details: Monday, November 11, 2024 at 3:00pm EST
Location: Boston, MA
Webcast Registration Link: https://wsw.com/webcast/guggen/sabs/1934789
A recording of the webcast will be accessible through the “Events” section of the Company’s website at https://ir.sab.bio/news-events/events.
About SAB BIO
SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: www.SAB.bio and follow SAB on LinkedIn.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the development and efficacy of our T1D program and other discovery programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:
Kaelan Hollon
khollon@sab.bio
Vice President of Communications
Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
When is SAB BIO (SABS) presenting at the Guggenheim Healthcare Conference 2024?
What is SAB BIO (SABS) currently developing?